Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study-Reference-Cited by-同舟云学术

Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study

Published:2020-01-11 Issue:3 Volume:43 Page:233-242
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Kolberg Hans-Christian,Colleoni Marco,Demetriou Georgia Savva,Santi Patricia,Tesch Hans,Fujiwara Yasuhiro,Tomasevic Zorica,Hanes Vladimir

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-019-00886-3.pdf

Reference13 articles.

1. Genentech. Herceptin® (trastuzumab) prescribing information. South San Francisco: Genentech; 2018.

2. Roche Pharma AG. Herceptin® (trastuzumab) summary of product characteristics. Grenzach-Wyhlen: Roche Pharma AG; 2018.

3. von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018;19(7):987–98.

4. Burki TK. Trastuzumab cardiotoxicity in early-stage breast cancer. Lancet Oncol. 2016;17(6):e226.

5. Amgen NV. Kanjinti (trastuzumab) summary of product characteristics. Diegem: Amgen NV; 2018.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging role of biosimilars: Focus on trastuzumab and metastatic human epidermal growth factor receptor 2-positive breast cancer;Results in Chemistry;2023-12

2. Safety and efficacy comparisons of intravenous trastuzumab biosimilars to the reference product medicine in treatment‐naïve and switch‐over patients with breast cancer: a systematic and meta‐analysis;Journal of Pharmacy Practice and Research;2023-09-27

3. Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN^®) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer;Molecular and Clinical Oncology;2023-03-24

4. Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer;Biomedicines;2022-08-21

5. Comparison of adverse effects of trastuzumab with other drug combinations for the treatment of breast cancer: A review;Indian Journal of Physiology and Pharmacology;2022-05-31